Last reviewed · How we verify
Mirtazapine/SNRIs
Mirtazapine is a tetracyclic antidepressant that blocks alpha-2 adrenergic receptors and serotonin 5-HT2 and 5-HT3 receptors, increasing norepinephrine and serotonin neurotransmission.
Mirtazapine is a tetracyclic antidepressant that blocks alpha-2 adrenergic receptors and serotonin 5-HT2 and 5-HT3 receptors, increasing norepinephrine and serotonin neurotransmission. Used for Major depressive disorder, Off-label use in anxiety disorders, insomnia, and appetite stimulation.
At a glance
| Generic name | Mirtazapine/SNRIs |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | Tetracyclic antidepressant |
| Target | Alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
Mirtazapine enhances noradrenergic and serotonergic activity in the central nervous system through presynaptic alpha-2 antagonism and postsynaptic 5-HT2/5-HT3 receptor antagonism. This dual mechanism increases the release and availability of norepinephrine and serotonin, which are implicated in mood regulation. The drug is distinct from SNRIs (serotonin-norepinephrine reuptake inhibitors) in its mechanism, though both classes are used for similar psychiatric indications.
Approved indications
- Major depressive disorder
- Anxiety disorders
- Insomnia (off-label)
Common side effects
- Sedation
- Weight gain
- Increased appetite
- Dizziness
- Dry mouth
- Constipation
Key clinical trials
- eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk (PHASE2)
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
- Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics (PHASE4)
- Treatment of Mood and Marriage Study (TOMMS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirtazapine/SNRIs CI brief — competitive landscape report
- Mirtazapine/SNRIs updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI